What prior art in laboratory and domesticated species can teach product developers

Reading time: 9 minutes

The preceding articles in this Pillar 3 series addressed positioning as a sequence of questions: which workflows your product serves, who else operates at those steps, whether users will pay to change, who the buyer is, and how to describe the product credibly. Each article assumed, implicitly, that the target workflow is established enough to be observed, shadowed, and evaluated. This final article addresses the case where it is not.

For some of the most consequential applications of developmental and stem cell biology — species preservation, cultured food production, human ageing and rejuvenation — the workflows are still being invented. The protocols are thin, the cell types are poorly characterised, the regulatory frameworks barely exist, and the number of people with hands-on experience is small. A TechBio company that wants to position a product for these applications faces a specific version of the positioning problem: the workflow you would normally map does not yet exist, and the competitive landscape is defined not by products on the market but by knowledge that has or has not been generated in other species.

This is where prior art from laboratory and domesticated species becomes a positioning resource. What has been learned in mouse, sheep, cattle, pig, and human systems over four decades of developmental and stem cell biology is not just a scientific archive. It is a map of what works, what fails, what transfers across species, and what must be re-discovered in each new context. For the product developer, that map can shorten the path from concept to application — or, if misread, extend it.

What prior art means in this context

Prior art, in the sense used here, is the accumulated experimental knowledge of how developmental and stem cell processes work in species where the biology has been studied in depth. This includes: the conditions under which cells from different species can be reprogrammed, expanded, differentiated, and maintained; the protocols that have been validated for specific applications; the failure modes that have been documented; and the tooling that has been developed to serve those protocols.

The species in which this knowledge is deepest — mouse, followed by human, followed by livestock species (cattle, pig, sheep) — were not chosen at random. They were selected because they served specific practical purposes: the mouse as a genetic model, humans as the target for clinical medicine, and livestock for breeding, reproduction, and agricultural output. The stem cell biology of these species was developed in service of those purposes, and the tools that exist reflect those purposes.

This matters for positioning because a tool developed for mouse iPSCs under research-grade conditions does not automatically serve human iPSCs under GMP conditions, and neither serves iPSCs from an endangered marsupial whose reprogramming biology is incompletely characterised. The prior art tells you what has been tried, what worked, and what the boundary conditions were. It does not tell you that the same approach will work in a species where those conditions have not been tested.

How prior art transfers and where it does not

The practical question for the product developer is what transfers and what does not. Four decades of comparative work provide a rough guide.

Reprogramming principles transfer broadly, but the details are species-specific. The basic architecture of cellular reprogramming — delivery of defined transcription factors to somatic cells, selection for colonies exhibiting pluripotent characteristics, expansion and characterisation — was established in mouse and then demonstrated in human cells. It has since been applied to cells from the northern white rhinoceros, several primate species, birds, and other taxa [1,2]. The principles are conserved. The specific factor cocktails, delivery methods, culture media, and selection criteria are not. A reprogramming reagent validated for human fibroblasts will not necessarily reprogram rhinoceros skin cells with the same efficiency. The tool developer who assumes universal applicability is making a positioning claim the biology does not support.

Culture conditions are not portable. The media, substrates, and growth factors that sustain pluripotent cells in one species frequently do not sustain them in another, or sustain them in a different state with different downstream properties. Mouse embryonic stem cells are maintained in a ground state of pluripotency using specific inhibitors. Human pluripotent stem cells are maintained in a primed state under different conditions. Bovine and porcine cells present further variations. A cell culture product positioned as "for pluripotent stem cells" without specifying species and pluripotency state is making a claim that collapses under examination. The prior art tells you which conditions have been validated for which species. It also tells you, by omission, where the conditions have not been established.

Differentiation protocols require species-level optimisation. Directing a pluripotent cell to become a specific mature cell type — a neuron, a cardiomyocyte, a gamete — follows signalling pathways that are evolutionarily conserved in broad outline but variable in molecular detail. The Pillar 1 article on key stem cell methods described the principal differentiation approaches. Translating them from the species where they were developed (usually mouse or human) to a new species requires re-optimisation of timing, factor concentrations, and selection markers. A TechBio product that assists directed differentiation is positioned against the specific species and protocols it has been validated for. Broader claims require broader validation.

Cloning and reproductive technology provide the longest track record. Somatic cell nuclear transfer (SCNT) — cloning — was achieved in sheep, cattle, mice, pigs, and other species over the 1990s and 2000s, producing a body of work on nuclear reprogramming, epigenetic memory, developmental competence, and the technical variables that determine success or failure [3]. For product developers targeting reproductive applications in less-studied species, this body of work is the most directly relevant prior art. It tells you which steps are rate-limiting (oocyte quality, nuclear-cytoplasmic compatibility, activation protocol), which variables matter most (cell cycle synchronisation, donor cell type), and where the species-specific barriers sit. A tool developed for oocyte manipulation in cattle may have direct relevance to the same step in a closely related species and no relevance at all in a distantly related one. The prior art defines the boundary.

What this means for positioning in emerging applications

For a TechBio company positioning a product for species preservation, cultured food, or rejuvenation research, the prior art has three practical uses.

It defines the starting workflow. Where the target application's workflow does not yet exist in mature form, the workflow from the best-characterised analogous species serves as the starting template. If you are building a cryopreservation tool for cells from an endangered species, the validated cryopreservation protocols for the most closely related laboratory or domesticated species are your starting point, your initial validation framework, and the basis for your first pilot proposal. The workflow identification article described how to map an existing workflow. For emerging applications, the equivalent step is to identify the closest established workflow in a related species and use it as the reference.

It defines the evidence your product needs. The prior art tells you what performance standards have been established in the reference species. A cryopreservation tool for bovine embryos is evaluated against known post-thaw viability rates, developmental competence data, and field pregnancy outcomes accumulated over decades. A cryopreservation tool for rhinoceros gametes does not yet have those benchmarks. The product developer must decide whether to validate against the bovine benchmarks (with stated caveats about species differences), against whatever limited data exists for the target species, or against both. The prior art frames the evidence question even when the target species has no evidence base of its own.

It identifies where the knowledge gaps sit. A 2024 workshop report in Development, convened by Revive & Restore and involving stem cell scientists, conservation biologists, and technology developers, examined how stem cell technologies can support wildlife conservation [1]. The report noted that reprogramming and in vitro gametogenesis have been demonstrated in a limited number of species and that protocols developed for mice or humans do not transfer directly to conservation-priority species. It also highlighted the need for stem cell technologies to extend beyond mammalian systems to birds, amphibians, and marine invertebrates — species groups where the developmental biology is substantially different from the mammalian framework most tools are built for [1].

For the product developer, these knowledge gaps are both a commercial risk and a commercial opportunity. The risk is that a product validated only in mammalian systems may not serve the emerging conservation market, which includes non-mammalian species. The opportunity is that a product designed from the outset with cross-species flexibility — modular culture platforms, species-adaptable reagent sets, characterisation tools with adjustable reference panels — may serve a broader market than one locked to a single species framework.

The prior-art trap

Prior art can also mislead. The most common form of the trap is to treat prior art as proof rather than as a starting hypothesis. A team that has validated a product in mouse and human systems may assume, on the basis of that validation, that the product will work in any mammalian species. The biological basis for that assumption is weak. The evolutionary distance between a mouse and a rhinoceros, or between a human and a whale, is measured in tens of millions of years. Conserved molecular pathways diverge at the level of regulatory elements, expression timing, and protein-protein interactions. A product positioned on the claim "works in mouse and human, therefore works across species" is making a prediction the biology does not support.

The honest positioning is narrower and more useful: "validated in mouse and human systems under defined conditions; provides a starting point for adaptation to other species; species-specific validation required before performance can be claimed". This statement is less exciting and more credible. It is also a more accurate description of what the product can currently do, which is what a buyer evaluating it for a new species will want to know.

Where this connects to the rest of the series

This article brings the Pillar 3 series full circle. The positioning framework described across these articles applies to all ancillary TechBio products, but the degree of difficulty varies with the maturity of the target application. For cell therapy manufacturing, the workflows exist, the buyers are identifiable, and the competitive landscape is readable. For species preservation and rejuvenation research, the workflows are nascent, the buyer population is small and scattered, and the prior art from established species is the primary positioning resource.

The six-question framework remains the same: which workflows, which competitors, which demand, which buyer, which language, which prior art. What changes is where the weight falls. For mature applications, the weight is on workflow mapping and demand validation. For emerging applications, the weight is on prior art and on the honest assessment of what transfers and what must be discovered.

The Pillar 4 series on species preservation and the Pillar 5 series on ageing and rejuvenation will take these emerging applications as their primary subject, examining the biology, the bottlenecks, and the opportunities in depth. The Pillar 1 series provides the biological foundation for readers encountering these topics for the first time. The Pillar 2 series provides the failure-mode analysis against which all positioning decisions should be tested.

References

[1] Hutchinson AM, Appeltant R, Burdon T, et al. Advancing stem cell technologies for conservation of wildlife biodiversity. Development. 2024;151(20):dev203116. DOI: 10.1242/dev.203116

[2] Korody ML, Ford SM, Nguyen TD, et al. Rewinding Extinction in the Northern White Rhinoceros: Genetically Diverse Induced Pluripotent Stem Cell Bank for Genetic Rescue. Stem Cells Dev. 2021;30(4):177-189. DOI: 10.1089/scd.2021.0001

[3] Wilmut I, Beaujean N, De Sousa PA, Dinnyes A, King TJ, Paterson LA, Wells DN, Young LE. Somatic cell nuclear transfer. Nature. 2002;419(6907):583-586. DOI: 10.1038/nature01079

About StemCells.Help

StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.

ORCID: 0000-0003-0745-2504

Web: stemcells.help